Pontine Glioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Pontine Glioma Pipeline Drugs Market Overview
Pontine gliomas are highly aggressive and difficult-to-treat brain tumors found at the base of the brain. One of the most common types is diffuse intrinsic pontine glioma (DIPG). DIPG affects the pons portion of the brainstem, rendering nervous system function impossible. Symptoms include double vision, inability to close the eyelids completely, dropping one side of the face, and difficulty chewing and swallowing.
The pontine glioma pipeline drugs market research report provides comprehensive information on the therapeutics under development for pontine glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for pontine glioma and features dormant and discontinued projects.
Pontine Glioma Pipeline Drugs Market Segmentation by Targets
Some of the targets of the pontine glioma pipeline drugs market are Cells Expressing CD276 Antigen, Cyclin Dependent Kinase 4, Cyclin Dependent Kinase 6, Histone Deacetylase, Programmed Cell Death Protein 1, Signal Transducer and Activator of Transcription 3, Baculoviral IAP Repeat Containing Protein 5, Cells Expressing Integrin Beta 5, and others.
Pontine Glioma Pipeline Drugs Market Analysis, by Targets
For more Pontine Glioma pipeline drugs market target insights, download a free report sample
Pontine Glioma Pipeline Drugs Market Segmentation by Mechanisms of Action
Some of the key mechanisms of action of the Pontine Glioma pipeline drugs market are Cytotoxic To Cells Expressing CD276 Antigen, Cyclin Dependent Kinase 4 Inhibitor, Cyclin Dependent Kinase 6 Inhibitor, Histone Deacetylase Inhibitor, Programmed Cell Death Protein 1 Antagonist, Signal Transducer And Activator Of Transcription 3 Inhibitor, Cytotoxic To Cells Expressing Integrin Beta 5, Cytotoxic To Cells Expressing Wilms Tumor Protein, and others.
Pontine Glioma Pipeline Drugs Market Analysis, by Mechanisms of Action
For more mechanisms of action insights into the Pontine Glioma pipeline drugs market, download a free report sample
Pontine Glioma Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the Pontine Glioma pipeline drugs market are oral, intravenous, intratumor, subcutaneous, intraperitoneal, intradermal, intracerebral, intravenous drip, and others.
Pontine Glioma Pipeline Drugs Market Analysis, by Routes of Administration
For more routes of administration insights into the Pontine Glioma pipeline drugs market, download a free report sample
Pontine Glioma Pipeline Drugs Market Segmentation by Molecule Types
The molecule types in the Pontine Glioma pipeline drugs market are Small Molecule, Monoclonal Antibody, Subunit Vaccine, Cell Therapy, Gene-Modified Cell Therapy, Monoclonal Antibody Conjugated, Antisense Oligonucleotide, Fusion Protein, and others.
Pontine Glioma Pipeline Drugs Market Analysis, by Molecule Types
For more molecule type insights into the Pontine Glioma pipeline drugs market, download a free report sample
Pontine Glioma Pipeline Drugs Market - Competitive Landscape
Some of the key companies in the Pontine Glioma pipeline drugs market are Bristol-Myers Squibb Co, Accendatech Co Ltd, DNAtrix Inc, Midatech Pharma Plc, Novartis AG, Y-mAbs Therapeutics Inc, A. Menarini Industrie Farmaceutiche Riunite Srl, Aminex Therapeutics Inc, Apexigen Inc, and others.
Pontine Glioma Pipeline Drugs Market Analysis, by Companies
To know more about the Pontine Glioma pipeline drugs market companies, download a free report sample
Pontine Glioma Pipeline Drugs Market Report Overview
| Key Targets | Cells Expressing CD276 Antigen, Cyclin Dependent Kinase 4, Cyclin Dependent Kinase 6, Histone Deacetylase, Programmed Cell Death Protein 1, Signal Transducer and Activator Of Transcription 3, Baculoviral IAP Repeat Containing Protein 5, Cells Expressing Integrin Beta 5, and Others |
| Key Mechanisms of Action | Cytotoxic To Cells Expressing CD276 Antigen, Cyclin Dependent Kinase 4 Inhibitor, Cyclin Dependent Kinase 6 Inhibitor, Histone Deacetylase Inhibitor, Programmed Cell Death Protein 1 Antagonist, Signal Transducer and Activator Of Transcription 3 Inhibitor, Cytotoxic To Cells Expressing Integrin Beta 5, Cytotoxic To Cells Expressing Wilms Tumor Protein, and Others |
| Key Routes of Administration | Oral, Intravenous, Intratumor, Subcutaneous, Intraperitoneal, Intradermal, Intracerebral, Intravenous Drip, and Others |
| Key Molecule Types | Small Molecule, Monoclonal Antibody, Subunit Vaccine, Cell Therapy, Gene-Modified Cell Therapy, Monoclonal Antibody Conjugated, Antisense Oligonucleotide, Fusion Protein, and Others |
| Key Companies | Bristol-Myers Squibb Co, Accendatech Co Ltd, DNAtrix Inc, Midatech Pharma Plc, Novartis AG, Y-mAbs Therapeutics Inc, A. Menarini Industrie Farmaceutiche Riunite Srl, Aminex Therapeutics Inc, Apexigen Inc, and Others |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Pontine Glioma.
- The pipeline guide reviews pipeline therapeutics for Pontine Glioma by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pontine Glioma therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pontine Glioma therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Pontine Glioma
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pontine Glioma.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding the Pontine Glioma pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.
Accendatech Co Ltd
Aminex Therapeutics Inc
Apexigen Inc
Bayer AG
Bexion Pharmaceuticals LLC
BioMarin Pharmaceutical Inc
Bionaut Labs Inc
Bristol-Myers Squibb Co
CDG Therapeutics Inc
Chimerix Inc
Cothera Bioscience Pty Ltd
Curis Inc
DNAtrix Inc
Eisai Co Ltd
Eli Lilly and Co
Exelixis Inc
F. Hoffmann-La Roche Ltd
Gate2Brain SL
ImmunityBio Inc
Immunomic Therapeutics Inc
Incuron
InnoMab Pte Ltd
Karyopharm Therapeutics Inc
Kazia Therapeutics Ltd
Lumos Pharma Inc
M4K Pharma Inc
Mana Therapeutics Inc
Medicenna Therapeutics Corp
Midatech Pharma Plc
MimiVax LLC
Moleculin Biotech Inc
Novartis AG
Oblato Inc
OncoRx Pharmaceuticals Inc
Oncotelic Therapeutics Inc
Ono Pharmaceutical Co Ltd
Pfizer Inc
Plus Therapeutics Inc
PTC Therapeutics Inc
Regeneron Pharmaceuticals Inc
Secura Bio Inc
Shionogi & Co Ltd
TCR Cure Biopharma Technology Co Ltd
Tmunity Therapeutics Inc
Xcovery Holding Co LLC
Y-mAbs Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets of the Pontine Glioma pipeline drugs market?
Some of the targets of the Pontine Glioma pipeline drugs market are Cells Expressing CD276 Antigen, Cyclin Dependent Kinase 4, Cyclin Dependent Kinase 6, Histone Deacetylase, Programmed Cell Death Protein 1, Signal Transducer and Activator Of Transcription 3, Baculoviral IAP Repeat Containing Protein 5, Cells Expressing Integrin Beta 5, and others.
-
What are the key mechanisms of action in the Pontine Glioma pipeline drugs market?
Some of the mechanisms of action of the Pontine Glioma pipeline drugs market are Cytotoxic To Cells Expressing CD276 Antigen, Cyclin Dependent Kinase 4 Inhibitor, Cyclin Dependent Kinase 6 Inhibitor, Histone Deacetylase Inhibitor, Programmed Cell Death Protein 1 Antagonist, Signal Transducer And Activator Of Transcription 3 Inhibitor, Cytotoxic To Cells Expressing Integrin Beta 5, Cytotoxic To Cells Expressing Wilms Tumor Protein, and others.
-
What are the key routes of administration in the Pontine Glioma pipeline drugs market?
The key routes of administration in the Pontine Glioma pipeline drugs market are oral, intravenous, intratumor, subcutaneous, intraperitoneal, intradermal, intracerebral, intravenous drip, and others.
-
What are the key molecule types in the Pontine Glioma pipeline drugs market?
The molecule types in the Pontine Glioma pipeline drugs market are Small Molecule, Monoclonal Antibody, Subunit Vaccine, Cell Therapy, Gene-Modified Cell Therapy, Monoclonal Antibody Conjugated, Antisense Oligonucleotide, Fusion Protein, and others.
-
Which are the leading companies in the Pontine Glioma pipeline drugs market?
Some of the leading companies in the Pontine Glioma pipeline drugs market are Bristol-Myers Squibb Co, Accendatech Co Ltd, DNAtrix Inc, Midatech Pharma Plc, Novartis AG, Y-mAbs Therapeutics Inc, A. Menarini Industrie Farmaceutiche Riunite Srl, Aminex Therapeutics Inc, Apexigen Inc, and others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Sample Report
Pontine Glioma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Oncology reports